Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients
C. Cariti
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Equally contributed to this study and shared first authorship.Search for more papers by this authorP. Dapavo
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Equally contributed to this study and shared first authorship.Search for more papers by this authorL. Mastorino
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Equally contributed to this study and shared first authorship.Search for more papers by this authorM. Ortoncelli
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorN. Siliquini
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorM. Merli
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorG. Avallone
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorS. Giordano
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorR. Fabrizio
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorS. Susca
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorA. Verrone
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorE. Stroppiana
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorP. Quaglino
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Shared last authorship.Search for more papers by this authorCorresponding Author
S. Ribero
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Shared last authorship.*Correspondence: S. Ribero. E-mail: [email protected]
Search for more papers by this authorC. Cariti
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Equally contributed to this study and shared first authorship.Search for more papers by this authorP. Dapavo
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Equally contributed to this study and shared first authorship.Search for more papers by this authorL. Mastorino
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Equally contributed to this study and shared first authorship.Search for more papers by this authorM. Ortoncelli
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorN. Siliquini
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorM. Merli
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorG. Avallone
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorS. Giordano
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorR. Fabrizio
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorS. Susca
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorA. Verrone
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorE. Stroppiana
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Search for more papers by this authorP. Quaglino
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Shared last authorship.Search for more papers by this authorCorresponding Author
S. Ribero
Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 – 10126 Italy
Shared last authorship.*Correspondence: S. Ribero. E-mail: [email protected]
Search for more papers by this authorOpen Research
Data availability statement
Data are available upon reasonable request.
References
- 1Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol 2019; 33: 355–366.
- 2Chiricozzi A, Balato A, Conrad C et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentre, retrospective, real-world study. J Dermatolog Treat 2020; 31: 476–483.
- 3Deza G, Notario J, Lopez-Ferrer A et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2019; 33: 553–559.
- 4Blauvelt A, Shi N, Burge R et al. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab. J Am Acad Dermatol 2020; 82: 927–935.
- 5Warren RB, Brnabic A, Saure D et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol 2018; 178: 1064-1071.
- 6Torres T, Puig L, Vender R et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol 2021; 30: 567–579.
- 7Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA et al. Comparative study of the efficacy and safety of secukinumab vs. ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther. 2020; 33: e13313.
- 8Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat 2018; 29: 569–578.
Citing Literature
